Literature DB >> 21958003

The genetics of the human APOE polymorphism.

Davide Seripa1, Grazia D'Onofrio, Francesco Panza, Leandro Cascavilla, Carlo Masullo, Alberto Pilotto.   

Abstract

Abstract The genetic origin of the three common variants of the human apolipoprotein E (apoE) protein, known as E2, E3 and E4, was understood in 1981, and since the mid 1980s these are probably the most-studied protein variants in human races. They have been related to a number of age-related diseases, including Alzheimer disease, as well as to healthy aging and longevity. The gene variants underlying these protein isoforms, known as ε2, ε3, and ε4, are allelic forms of the APOE gene, resulting from different haplotypes at the APOE locus (19q13.31). In particular, they result from three of the four haplotypes expected by the combinations of the alleles of the two single-nucleotide polymorphisms rs429358 and rs7412. The fourth missing haplotype, known as ε3r, has been identified in only two Caucasian families from Italy and in one Yoruba family from Nigeria worldwide. Thus, this fourth APOE gene variant is rare, and it encodes a protein isoform, identified as E3r, showing identical physical characteristics to E3, that conversely, is the most common form of apoE in humans. In this review article, we report the identification of the haplotype ε3r in a third Caucasian family from Italy, and then attempt to re-examine the current knowledge regarding the APOE polymorphism, taking into account this fourth haplotype. We also focus on the commonly accepted hypothesis for the evolution of the common APOE gene variants, in which we include the ε3r haplotype, previously not considered.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21958003     DOI: 10.1089/rej.2011.1169

Source DB:  PubMed          Journal:  Rejuvenation Res        ISSN: 1549-1684            Impact factor:   4.663


  32 in total

1.  Evidence from case-control and longitudinal studies supports associations of genetic variation in APOE, CETP, and IL6 with human longevity.

Authors:  Mette Soerensen; Serena Dato; Qihua Tan; Mikael Thinggaard; Rabea Kleindorp; Marian Beekman; H Eka D Suchiman; Rune Jacobsen; Matt McGue; Tinna Stevnsner; Vilhelm A Bohr; Anton J M de Craen; Rudi G J Westendorp; Stefan Schreiber; P Eline Slagboom; Almut Nebel; James W Vaupel; Kaare Christensen; Lene Christiansen
Journal:  Age (Dordr)       Date:  2012-01-12

2.  Amyloid-Related Imaging Abnormalities in an Aged Squirrel Monkey with Cerebral Amyloid Angiopathy.

Authors:  Eric Heuer; Jessica Jacobs; Rebecca Du; Silun Wang; Orion P Keifer; Amarallys F Cintron; Jeromy Dooyema; Yuguang Meng; Xiaodong Zhang; Lary C Walker
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

Review 3.  Role of Pharmacogenomics in Individualizing Treatment for Alzheimer's Disease.

Authors:  Natalie Argueta; Emily Notari; Kinga Szigeti
Journal:  CNS Drugs       Date:  2022-03-30       Impact factor: 5.749

Review 4.  APOE in the bullseye of neurodegenerative diseases: impact of the APOE genotype in Alzheimer's disease pathology and brain diseases.

Authors:  Rosalía Fernández-Calle; Sabine C Konings; Javier Frontiñán-Rubio; Juan García-Revilla; Lluís Camprubí-Ferrer; Martina Svensson; Isak Martinson; Antonio Boza-Serrano; José Luís Venero; Henrietta M Nielsen; Gunnar K Gouras; Tomas Deierborg
Journal:  Mol Neurodegener       Date:  2022-09-24       Impact factor: 18.879

5.  Sirt1 is involved in decreased bone formation in aged apolipoprotein E-deficient mice.

Authors:  Wei Hong; Xiao-ya Xu; Zhao-hui Qiu; Jian-jun Gao; Zhan-ying Wei; Li Zhen; Xiao-li Zhang; Zhi-bing Ye
Journal:  Acta Pharmacol Sin       Date:  2015-11-23       Impact factor: 6.150

6.  Antioxidant status and APOE genotype as susceptibility factors for neurodegeneration in Alzheimer's disease and vascular dementia.

Authors:  Giancarlo Zito; Renato Polimanti; Valentina Panetta; Mariacarla Ventriglia; Carlo Salustri; Maria Cristina Siotto; Filomena Moffa; Claudia Altamura; Fabrizio Vernieri; Domenico Lupoi; Emanuele Cassetta; Paolo M Rossini; Rosanna Squitti
Journal:  Rejuvenation Res       Date:  2013-02       Impact factor: 4.663

7.  Human ApoE Isoforms Differentially Modulate Glucose and Amyloid Metabolic Pathways in Female Brain: Evidence of the Mechanism of Neuroprotection by ApoE2 and Implications for Alzheimer's Disease Prevention and Early Intervention.

Authors:  Jeriel Thomas-Richard Keeney; Shaher Ibrahimi; Liqin Zhao
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

8.  Apolipoprotein E4 prevents growth of malaria at the intraerythrocyte stage: implications for differences in racial susceptibility to Alzheimer's disease.

Authors:  Hisashi Fujioka; Clyde F Phelix; Robert P Friedland; Xiongwei Zhu; Elizabeth A Perry; Rudy J Castellani; George Perry
Journal:  J Health Care Poor Underserved       Date:  2013-11

9.  APOε2 and education in cognitively normal older subjects with high levels of AD pathology at autopsy: findings from the Nun Study.

Authors:  Diego Iacono; Peter Zandi; Myron Gross; William R Markesbery; Olga Pletnikova; Gay Rudow; Juan C Troncoso
Journal:  Oncotarget       Date:  2015-06-10

10.  Induction of mitochondrial changes associated with oxidative stress on very long chain fatty acids (C22:0, C24:0, or C26:0)-treated human neuronal cells (SK-NB-E).

Authors:  Amira Zarrouk; Anne Vejux; Thomas Nury; Hammam I El Hajj; Madouda Haddad; Mustapha Cherkaoui-Malki; Jean-Marc Riedinger; Mohamed Hammami; Gérard Lizard
Journal:  Oxid Med Cell Longev       Date:  2012-08-05       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.